Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,129
  • Shares Outstanding, K 28,007
  • Annual Sales, $ 0 K
  • Annual Income, $ -62,720 K
  • EBIT $ -63 M
  • EBITDA $ -60 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +34.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +3.15%
on 11/08/24
1.6000 -18.13%
on 11/12/24
-0.0600 (-4.38%)
since 10/18/24
3-Month
1.2700 +3.15%
on 11/08/24
1.6500 -20.61%
on 08/28/24
-0.3200 (-19.63%)
since 08/19/24
52-Week
1.0300 +27.18%
on 12/14/23
2.5700 -49.03%
on 04/02/24
+0.0300 (+2.34%)
since 11/17/23

Most Recent Stories

More News
NextCure, Inc. Reports Promising Preclinical Data for NC605 in Osteogenesis Imperfecta Treatment

NextCure presented promising preclinical data on NC605, an antibody that enhances bone quality in Osteogenesis Imperfecta.Quiver AI SummaryNextCure, Inc. has announced promising preclinical data showcasing...

NXTC : 1.3100 (+1.55%)
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NXTC : 1.3100 (+1.55%)
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

NXTC : 1.3100 (+1.55%)
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NXTC : 1.3100 (+1.55%)
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NXTC : 1.3100 (+1.55%)
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 21.64 (-6.68%)
NXTC : 1.3100 (+1.55%)
BHVN : 46.30 (+1.96%)
INZY : 2.81 (-2.43%)
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.3100 (+1.55%)
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.3100 (+1.55%)
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.3100 (+1.55%)
NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

NXTC : 1.3100 (+1.55%)

Business Summary

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland....

See More

Key Turning Points

3rd Resistance Point 1.5000
2nd Resistance Point 1.4500
1st Resistance Point 1.3800
Last Price 1.3100
1st Support Level 1.2600
2nd Support Level 1.2100
3rd Support Level 1.1400

See More

52-Week High 2.5700
Fibonacci 61.8% 1.9817
Fibonacci 50% 1.8000
Fibonacci 38.2% 1.6183
Last Price 1.3100
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar